Field report N-85 / Q6 · sheet /strategy

Corporate StrategyFiled from the territory

Stryker's Lobo: Two of Three Knee Replacements Now Robotic, and No Robots Will Be Built in China

Stryker CEO Kevin Lobo says two of three knee replacements are now robotic, Mako IP stays in the U.S., and a $400 million CMR Surgical deal targets soft tissue.

Grid
N-85 / Q6
Surveyed
November 18, 2026
Reading
5 min read
Correspondent
Priya Raman
Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements—and he won’t build them in China because ‘the I
Fig. N-85 / Q6Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements—and he won’t build them in China because ‘the I — hysw001 / pixabay

Field notes

  1. Two of every three Stryker knee replacements are now performed robotically with the Mako system, used in 2.5 million procedures across 47 countries.
  2. Lobo said Stryker has "no plans" to build robots in China: "The IP is a massive worry."
  3. In October Stryker agreed to a roughly $400 million preferred-equity investment in CMR Surgical with an exclusive option to buy the company.
  4. Stryker cut its 2026 organic sales growth forecast to 6.5%-7%, from 8.3%-9.3% guided in July.
  5. China's MicroPort MedBot reported 300 global Toumai orders and capacity to build 500 robots a year.

Two of every three knee replacements Stryker performs are now done robotically, and CEO Kevin Lobo says the company will never build those robots in China because intellectual property theft is, in his words, "a massive worry."

"We have no plans to make any robots in China. The IP is a massive worry," Lobo said Monday at the Fortune 500 Innovation Forum in Detroit. "They are knocking off a lot of the other robots."

The comment cuts to the heart of Stryker's strategy. Its Mako surgical robot has been used in 2.5 million procedures across 47 countries, which makes the machine's intellectual property a core part of what hospitals are actually buying when they sign with the Michigan-based device maker.

Why does China worry Stryker so much?

Chinese competitors are scaling fast. MicroPort MedBot, a Shanghai-based firm that makes the Toumai soft-tissue surgical robot, said in June it had passed 300 global orders, been installed in more than 60 countries, and can build up to 500 robots a year.

Lobo, who serves as Stryker's chair and CEO, also noted that one of Stryker's "major competitors" had bought into a Chinese robotics company. He declined to name it.

Asked by Fortune's Andrew Nusca whether the U.S.-China race in robotics turns on talent, IP or supply chains, Lobo said Stryker builds its robots at home and ships them worldwide. He added that Stryker is "scouring the market" to see whether Chinese companies can develop new kinds of robots for other parts of the anatomy.

His assessment of the competitive threat was blunt. Engineering talent alone doesn't win in surgery, he argued, because clinical experience matters more.

"They can have the best engineers. If they don't have the domain experience clinically, it's not going to be so easy," Lobo said. "So we don't see them as kind of an imminent threat to our businesses."

Stryker views Chinese companies "more opportunistically," he said, "and we're being very thoughtful about not making anything there that can be taken from."

What makes the Mako robot valuable?

Precision, according to Lobo. The surgeon stays in the room, but the Mako arm makes the cuts, following a surgical plan built from a CT scan, with haptic boundary controls (vibration-based limits that stop the instrument straying) that he said deliver one-millimeter precision. If a surgeon tries to cut outside the planned boundaries, "the robot won't let them."

One surgeon recently told Lobo the technology makes him feel like he's almost cheating.

Robotic assistance is becoming the standard of care, Lobo said. Orthopedic residents now ask one question first when choosing where to train: "What robots do you have?"

There's a data play too. All data the robot captures belongs to Stryker, subject to HIPAA (the U.S. patient-privacy law) and other rules, Lobo said. Stryker's customer contracts let the company use that data to show hospitals, for example, why one surgeon takes longer than another.

What is the $400 million soft-tissue bet?

Stryker's next move targets surgery beyond bones and joints. In October, it agreed to a roughly $400 million preferred-equity investment in CMR Surgical, a London company that makes the Versius soft-tissue robot. The deal makes Stryker the exclusive U.S. sales agent for Versius and grants an exclusive option to buy all of CMR later, according to Stryker.

Lobo pitched Versius as a smaller, cheaper alternative in a soft-tissue market he said has "only one big company" — Intuitive Surgical — whose robot is "extremely expensive and it's a giant robot." CMR's machine is about half the footprint, he said, and better suited to surgery centers doing gallbladder removals and hernia repairs.

CMR spent 10 years reaching this point, Lobo noted, but needs a company with Stryker's resources, "because small companies, it just takes too long." The deal remains subject to regulatory approvals.

Lobo also described the U.S. FDA as "very friendly for innovation, much more friendly in the United States than we're seeing in other countries around the world."

The timing matters. Stryker's hip and knee business has slowed. Last month the company cut its 2026 organic sales growth forecast to 6.5% to 7%, down from the 8.3% to 9.3% range it guided to in July.

"In addition to the softer market, we have not been winning at our historical rate," Lobo told analysts on the earnings call, though he said Mako sales "have been strong again this year."

Is robotics reshaping U.S. manufacturing too?

Wendy Tan White, CEO of Intrinsic — a robotics-software company that Alphabet moved into Google in February — shared the Detroit stage with Lobo and argued the China race extends well beyond surgery.

Cheaper hardware plus AI that lets robots see and adapt in real time means small U.S. manufacturers can now afford automation, she said. One customer, a small machine shop, uses a robot to tend a CNC milling machine and "can run an extra run overnight that they couldn't before," letting it compete on cost "rather than in Vietnam or somewhere else in the world."

"If you're going to bring reshore manufacturing back to somewhere like the U.S., you actually need to bring that cost down and that skill base back," she said. She called robotics "an enhancement to skilled working," not a replacement, because hardware remains limited by the physics of the real world.

As for the soft-tissue robots surgeons have been waiting for, Lobo promised they're close. "Trust me, it's coming, and it's going to come pretty fast," he said.

via fortune.com/feed/ (Source)

Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.

460 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetN-85 / Q6 · November 18, 2026